Headlines about Cancer Genetics (NASDAQ:CGIX) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cancer Genetics earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 44.4936053884808 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several analysts recently weighed in on CGIX shares. Maxim Group set a $6.00 price target on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, December 13th. HC Wainwright set a $6.00 price target on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, November 29th. Zacks Investment Research cut Cancer Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, ValuEngine cut Cancer Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $5.56.
Cancer Genetics (NASDAQ CGIX) opened at $2.00 on Friday. The company has a market capitalization of $55.41, a price-to-earnings ratio of -2.44 and a beta of 1.10. Cancer Genetics has a fifty-two week low of $1.60 and a fifty-two week high of $5.30. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18.
In other news, Director John Pappajohn acquired 150,000 shares of Cancer Genetics stock in a transaction that occurred on Friday, December 8th. The shares were acquired at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the transaction, the director now directly owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 21.30% of the company’s stock.
WARNING: “Cancer Genetics (CGIX) Getting Somewhat Favorable News Coverage, Analysis Shows” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/cancer-genetics-cgix-earning-somewhat-positive-press-coverage-study-shows.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.